The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026 ... Further boosting the pipeline, mid-stage drugs like ...

Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026 ... Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen ...

SNY Sanofi Dupixent® ... (COPD) Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Chronic obstructive pulmonary disease (COPD) has seen no new ... first regulator worldwide to approve Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent recently gained FDA approval for COPD, marking its sixth U.S. indication since its first use for atopic dermatitis ...

Medscape Medical News, August 10, 2023 COPD Plus PRISm May Promote ... Sustained in Trial The benefits of Sanofi and Regeneron's anti-inflammatory drug Dupixent set in quickly during a trial ...